Status:

COMPLETED

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy

Lead Sponsor:

AstraZeneca

Conditions:

Neuropathic Pain

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy.

Eligibility Criteria

Inclusion

  • Provision of signed informed consent form
  • Males and female of non-child bearing potential patients aged 18 to 80 years
  • Patients with neuropathic pain due to painful diabetic polyneuropathy.

Exclusion

  • Other pain that may confound assessment of neuropathic pain
  • History of treatment failure with more than three adequate trials of medication for neuropathic pain
  • Central neuropathic pain conditions (caused by Central Nervous System injury/disease, eg. Stroke)

Key Trial Info

Start Date :

September 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

134 Patients enrolled

Trial Details

Trial ID

NCT01201317

Start Date

September 1 2010

End Date

June 1 2011

Last Update

April 25 2014

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

Research Site

Goodyear, Arizona, United States

2

Research Site

Phoenix, Arizona, United States

3

Research Site

Tucson, Arizona, United States

4

Research Site

Los Angeles, California, United States